Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Full steam ahead
April 2020
SHARING OPTIONS:

NEW HAVEN, Conn.—Biohaven Pharmaceutical Holding Company Ltd. announced earlier this year that the FDA had granted permission for the initiation of a clinical trial for verdiperstat in amyotrophic lateral sclerosis (ALS). Verdiperstat is a novel inhibitor of myeloperoxidase (MPO), which increases oxidative stress and inflammation in the nervous system and has been implicated in several neurodegenerative diseases. The drug candidate will be included in the HEALEY ALS Platform Trial, which is being conducted by experts at the Sean M. Healey & AMG Center for Amyotrophic Lateral Sclerosis at Massachusetts General Hospital in collaboration with the Northeast ALS Consortium clinical trial network. Biohaven licensed verdiperstat from AstraZeneca in 2018, and is also evaluating the compound for the treatment of multiple system atrophy.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.